Pommier, Yves

γH2AX and cancer

Bonner, W. M., Redon, C. E., Dickey, J. S., Nakamura, A. J., Sedelnikova, O. A., Solier, S., & Pommier, Y. (2008) · Nature reviews. Cancer

DNA Repair MechanismsEffects of Radiation Exposure

Cited by 1,623

CellMiner: A Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set

Reinhold, W. C., Sunshine, M., Liu, H., Varma, S., Kohn, K. W., Morris, J., Doroshow, J., & Pommier, Y. (2012) · Cancer Research

Gene expression and cancer classificationComputational Drug Discovery Methods

Cited by 887

Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes

Furuta, T., Takemura, H., Liao, Z.-Y., Aune, G. J., Redon, C., Sedelnikova, O. A., Pilch, D. R., Rogakou, E. P., Celeste, A., Chen, H. T., et al. (2003) · Journal of Biological Chemistry

DNA Repair MechanismsCancer therapeutics and mechanisms

Cited by 449

Genome Organization Drives Chromosome Fragility

Canela, A., Maman, Y., Jung, S., Wong, N., Callen, E., Day, A., Kieffer-Kwon, K.-R., Pekowska, A., Zhang, H., Rao, S. S. P., et al. (2017) · Cell

Genomics and Chromatin DynamicsDNA Repair Mechanisms

Cited by 383

Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1

Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., & Melillo, G. (2004) · Cancer Research

Cancer therapeutics and mechanismsCancer, Hypoxia, and Metabolism

Cited by 301

Mutagenic Processing of Ribonucleotides in DNA by Yeast Topoisomerase I

Kim, N., Huang, S.-Y. N., Williams, J. S., Li, Y. C., Clark, A. B., Cho, J.-E., Kunkel, T. A., Pommier, Y., & Jinks-Robertson, S. (2011) · Science

DNA Repair MechanismsCancer therapeutics and mechanisms

Cited by 291

The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology

Abaan, O. D., Polley, E. C., Davis, S. R., Zhu, Y. J., Bilke, S., Walker, R. L., Pineda, M., Gindin, Y., Jiang, Y., Reinhold, W. C., et al. (2013) · Cancer Research

Cancer Genomics and DiagnosticsGenomics and Rare Diseases

Cited by 288

SLFN11 Blocks Stressed Replication Forks Independently of ATR

Murai, J., Tang, S.-W., Leo, E., Baechler, S. A., Redon, C. E., Zhang, H., Al Abo, M., Rajapakse, V. N., Nakamura, E., Jenkins, L. M. M., et al. (2018) · Molecular Cell

DNA Repair MechanismsChromatin Remodeling and Cancer

Cited by 275

Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)

Hare, S., Smith, S. J., Métifiot, M., Jaxa-Chamiec, A., Pommier, Y., Hughes, S. H., & Cherepanov, P. (2011) · Molecular Pharmacology

HIV/AIDS drug development and treatmentHIV Research and Treatment

Cited by 264

Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas

Kummar, S., Chen, A., Ji, J., Zhang, Y., Reid, J. M., Ames, M., Jia, L., Weil, M., Speranza, G., Murgo, A. J., et al. (2011) · Cancer Research

PARP inhibition in cancer therapyCancer therapeutics and mechanisms

Cited by 259

The intra-S phase checkpoint affects both DNA replication initiation and elongation: single-cell and -DNA fiber analyses

Seiler, J. A., Conti, C., Syed, A., Aladjem, M. I., & Pommier, Y. (2007) · Molecular and Cellular Biology

DNA Repair MechanismsCancer therapeutics and mechanisms

Cited by 226

Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies

Murai, J., Thomas, A., Miettinen, M., & Pommier, Y. (2019) · Pharmacology & Therapeutics

DNA Repair MechanismsCancer therapeutics and mechanisms

Cited by 172

DNA fingerprinting of the NCI-60 cell line panel

Lorenzi, P. L., Reinhold, W. C., Varma, S., Hutchinson, A. A., Pommier, Y., Chanock, S. J., & Weinstein, J. N. (2009) · Molecular Cancer Therapeutics

Cancer Genomics and DiagnosticsGene expression and cancer classification

Cited by 166

Optimal function of the DNA repair enzyme TDP1 requires its phosphorylation by ATM and/or DNA‐PK

Das, B. B., Antony, S., Gupta, S., Dexheimer, T. S., Redon, C. E., Garfield, S., Shiloh, Y., & Pommier, Y. (2009) · The EMBO Journal

DNA Repair MechanismsCancer therapeutics and mechanisms

Cited by 151

Viral Entry as the Primary Target for the Anti-HIV Activity of Chicoric Acid and Its Tetra-Acetyl Esters

Pluymers, W., Neamati, N., Pannecouque, C., Fikkert, V., Marchand, C., Burke, T. R., Pommier, Y., Schols, D., De Clercq, E., Debyser, Z., et al. (2000) · Molecular Pharmacology

HIV/AIDS drug development and treatmentHIV Research and Treatment

Cited by 111

Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 ( SLFN11) Expression with Class I Histone Deacetylase Inhibitors

Tang, S.-W., Thomas, A., Murai, J., Trepel, J. B., Bates, S. E., Rajapakse, V. N., & Pommier, Y. (2018) · Clinical Cancer Research

Histone Deacetylase Inhibitors ResearchEpigenetics and DNA Methylation

Cited by 94

Structure-activity relationship of pyrrolyl diketo acid derivatives as dual inhibitors of HIV-1 integrase and reverse transcriptase ribonuclease H domain

Cuzzucoli Crucitti, G., Métifiot, M., Pescatori, L., Messore, A., Madia, V. N., Pupo, G., Saccoliti, F., Scipione, L., Tortorella, S., Esposito, F., et al. (2015) · Journal of Medicinal Chemistry

HIV/AIDS drug development and treatmentComputational Drug Discovery Methods

Cited by 81

The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib

Marzi, L., Szabova, L., Gordon, M., Weaver Ohler, Z., Sharan, S. K., Beshiri, M. L., Etemadi, M., Murai, J., Kelly, K., & Pommier, Y. (2019) · Clinical Cancer Research

PARP inhibition in cancer therapyCancer therapeutics and mechanisms

Cited by 60

The FDA-Approved Anthelmintic Pyrvinium Pamoate Inhibits Pancreatic Cancer Cells in Nutrient-Depleted Conditions by Targeting the Mitochondria

Schultz, C. W., McCarthy, G. A., Nerwal, T., Nevler, A., DuHadaway, J. B., McCoy, M. D., Jiang, W., Brown, S. Z., Goetz, A., Jain, A., et al. (2021) · Molecular Cancer Therapeutics

Pancreatic and Hepatic Oncology ResearchCancer, Hypoxia, and Metabolism

Cited by 34

Abstract CT268: Targeting replication stress and chemotherapy resistance with a combination of sacituzumab govitecan and berzosertib: A phase I clinical trial

Abel, M. L., Takahashi, N., Desai, P., Peer, C., Redon, C., Nichols, S., Vilimas, R., Lee, M.-J., Lee, S., Sciuto, L., et al. (2023) · Cancer Research

Cancer therapeutics and mechanismsPARP inhibition in cancer therapy

Cited by 4